Cancer Center

The MCW Cancer Center is testing a new drug for advanced or metastatic triple-negative breast cancer, typically a more aggressive type of breast cancer with fewer good options for treatment. Studies have shown that African American women are more likely to have triple-negative breast cancer.

This study is to find out if a new drug, when used in combination with current treatments for triple-negative breast cancer, is more effective at treating this disease. Earlier studies of this new drug show that it could work better for African American women than for women from other backgrounds.

We also want to make sure that the experiences of African American patients with triple-negative breast cancer are shared with others in the medical field and see if this drug works better, or differently, for African American women.

Want to Learn More?  Talk to your doctor about this study, learn more at ClinicalTrials.gov, or contact the study coordinator: Cheryl Knapp, RN, Clinical Research Coordinator at (414) 805-8837 or chknapp@mcw.edu.

Search All Active Cancer Trials

For patients whose treatment for diffused large B cell lymphoma ended unsuccessfully, this clinical trial may present new possibilities, and help researchers gain a better understanding of this new frontier in medicine. CAR-T gene therapy adapts the patient’s own immune system to attack cancer cells that it once could not see. We are proud to be working on this first of a kind combination CAR-T therapy that focuses on two different proteins within the cancer cell, CD-19 and CD-20. This trial is also testing a novel inhouse method of creating the enhanced T cells, to offer patients a potentially faster, safer, and more precise tool to fight this cancer. 

Want to Learn More?

Talk to your doctor about this study, learn more at learn more at ClinicalTrials.gov, or contact the study coordinator Bob Thompson.

Search All Active Cancer Trials

The MCW Cancer Center is participating in a national phase I study testing the safety and efficacy of PNK-007 (natural killer cells derived from human cord blood hematopoietic stem cells) in combination with interleukin-2 in patients with relapsed and/or refractory acute myeloid leukemia. This is a first in human study, and an MCW patient was the very first person to receive this drug.  

Want to Learn More?

For more information, talk to your doctor, learn more at ClinicalTrials.gov or contact the study coordinator Bob Thompson.

Search All Active Cancer Trails

This trial utilizes accelerated partial breast irradiation in a preoperative setting, as opposed to the standard postoperative treatment. The study seeks to understand if this preoperative treatment will improve the toxicity profile of breast conservation therapy.

Want to Learn More?

For more information, talk to your doctor, learn more at ClinicalTrials.gov or contact the study coordinator Maria Pigsley.

Search All Active Cancer Trials

Gynecology Oncology has several innovative trials currently open, including a study for patients with advanced recurrent ovarian cancer, a patient population with few good options. Sponsored by Merck, this phase II study investigates the efficacy and safety of pembrolizumab, a PD-1 inhibitor that has shown success in treating other cancer types. 

Want to Learn More?

For more information, talk to your doctor, learn more at ClinicalTrials.gov or contact the study coordinator Qiana Christian. 

Search All Active Cancer Trials

This National Institutes of Health-funded study is for patients with chronic myelogenous leukemia (CML), a blood cancer which is commonly treated with oral medication called Tyrosine kinase inhibitors (TKIs). The current recommendation for CML patients is to continue TKIs therapy indefinitely, despite high costs and significant side effects that decrease patients' health-related quality of life. This study discontinues TKI therapy in 170 willing and eligible CML patients and monitors them closely for 3 years in order to characterize: 

• Factors associated with CML recurrence
• Patient-reported health status changes after TKI discontinuation
• Patient decision making regarding TKI discontinuation with monitoring

This multi-institution study was launched at 15 sites across the nation including the MCW Cancer Center. Previous research in France suggested that some patients were able to discontinue medication and remain in remission, but this is the first study conducted in the United States. Study inclusion criteria include patients who have been on medication for at least three years and in remission for at least two.

Search All Active Cancer Trials